The pharmaceutical supply chain is a complex system with high stakes. USP provides insights on how it is helping industry navigate global disruptions and procurement issues.
|Articles|December 10, 2013
PharmTech's Industry Pipeline - sample
View the latest products and services from these sponsors.
Advertisement
Chemicals, Raw Materials, Intermediates, & Excipients
Cleanroom Equipment & Supplies
Information Technology
Laboratory Equipment & Supplies
Manufacturing Equipment & Supplies
Outsourcing & Consulting Services
Dermatology product development guidance from Dow.
Packaging Equipment & Supplies
Transfer packaging for prefillable syringes.
Miscellaneous
Advertisement
Related to this article
Jaenisch, Muraru, and Pandey discuss how regulators will audit pharma against its own AI policies and ways QA and regulatory teams can build defensible, inspection-ready AI practices.
Impurity deficiencies in submissions are remarkably consistent. Subathra Ramamoorthy, Veranova, explains how to catch them before agency filing.
USP’s Sheehan and Liu talk at AAPS PharmSci 360 abou getting novel excipients past the monograph hurdle through early engagement with FDA.
CDMOs announced expansions, exhibitors showcased automated equipment, and supply chain strategy discussions were a focus at CPHI Milan 2026.
Mitigating nitrosamine risk requires assessing each product individually and chasing zero nitrite in pharmaceutical excipients is often impractical and costly.
The business case for regulated AI turns on the cost of producing an outcome that the quality system can accept.
In October, FDA reorganized rare disease development around a fit-for-purpose framework and a new pathway for individualized gene editing. Regulators in Europe and the UK set out long-term plans for clinical trials, AI, and moving away from animal testing.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Improving Oral Peptide Delivery Through Structural Modifications
2
Using OEE Monitoring to Justify Expenditure on Aging Production Lines
3
Regulatory Roundup—October 2026: FDA Advances Rare Disease Development and Transparency Efforts
4
RRP Accelerated Approval: What VOCERYQ Means for Manufacturing Teams
5